Practice Management Alert

August Recipe for Billing Success

Payers Say Xolair Shots Are Not Chemotherapy Be on the lookout for some official guidance on reporting encounters in which your physician injects a patient with Xolair.

When reporting Xolair (aka omalizumab) shots, use standard injection codes, not chemotherapy codes, CPT's Drug Infusion Workgroup recommends.

The workgroup recently met to discuss the application of the injection codes, but no official word has been handed down yet, says Vicky O-Neil, CPC, CCS-P, president of The Hazlett Group in St. Louis. Still, you should get used to injection codes for Xolair, experts say, because it is difficult to justify the higher-paying chemotherapy code when injecting Xolair.

Best bet: Follow this advice when reporting Xolair injections for your patients--and wait for official word soon from CPT. Asthma Patients Get Xolair Most Often Xolair is a monoclonal antibody the physician injects to treat asthma. When your office nurse injects the substance under physician supervision, you should always report 90772 (Therapeutic, prophylactic or diagnostic injection [specify substance or drug]; subcutaneous or intramuscular) for the service, says a recent Cigna Government Services release.

Example: An established patient with extrinsic asthma reports for a Xolair injection and an asthma evaluation. Your doctor sees the patient, and then the nurse administers 300 mg of Xolair by injection into the patient and sends him home. On the claim, you should:

- report 90772 for the Xolair injection.

- report J2357 (Injection, omalizumab, 5 mg) x 60 for the supply of Xolair.

- report the appropriate evaluation and management (E/M) level from 99211-99215 for the office visit.

- append modifier 25 (Significant, separately identifiable evaluation and management service by the same physician on the same day of the procedure or other service) to the E/M code to show that the E/M was separate from the injection.

- link ICD-9 code 493.00 (Extrinsic asthma; unspecified) to 90772, J2357 and the E/M code to indicate the medical necessity for the office visit and the Xolair injection. You must also back your Xolair injection claims with strong documentation. Check out these documentation requirements for Xolair injections, from Cigna's North Carolina Local Coverage Determination (LCD):

- -Office records must clearly document the reason and frequency for the drug (Xolair) use.-

- -The documentation must reflect the dose administered, the current weight of the beneficiary, and the initial IgE level.-

- -This information and an appropriate history and physical examination must be available if requested by the carrier to determine coverage.- Not only has Cigna instructed providers to use 90772 for Xolair shots, but it has gone out of its way to discourage the use of 96401 (Chemotherapy administration, subcutaneous or intramuscular; nonhormonal anti-neoplastic) for Xolair injections. The Cigna release states, -it would be incorrect to bill for administration of Xolair under 96401.-

Why? -Xolair is not an [...]
You’ve reached your limit of free articles. Already a subscriber? Log in.
Not a subscriber? Subscribe today to continue reading this article. Plus, you’ll get:
  • Simple explanations of current healthcare regulations and payer programs
  • Real-world reporting scenarios solved by our expert coders
  • Industry news, such as MAC and RAC activities, the OIG Work Plan, and CERT reports
  • Instant access to every article ever published in Revenue Cycle Insider
  • 6 annual AAPC-approved CEUs
  • The latest updates for CPT®, ICD-10-CM, HCPCS Level II, NCCI edits, modifiers, compliance, technology, practice management, and more

Which Codify by AAPC tool is right for you?

Call 844-334-2816 to speak with a Codify by AAPC specialist now.